Physician profile
Robert B Wilson
NPI 1922041326
$2,156.93
in general payments reported to CMS, 2019-2025
23 companies · $1,010 in 2025
The $1,010 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.26 · 2022: $31.18 · 2023: $74.49 · 2024: $1,026 · 2025: $1,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,110.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $414.13 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $290.66 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $245.10 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $225.28 | 2024-2025 | |
| Lilly USA, LLC | $198.71 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Amgen INC. | $143.81 | 2022-2025 | Otezla, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.80 | 2024-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $93.29 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.05 | 2025 | Caplyta |
| Corium, LLC | $48.45 | 2024 | Azstarys |
| Ironwood Pharmaceuticals, INC | $36.48 | 2023-2024 | Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.72 | 2024-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $30.25 | 2024-2025 | Gemtesa |
| Gilead Sciences, INC. | $26.13 | 2024 | Epclusa |
| Glaxosmithkline, LLC. | $26.03 | 2025 | Trelegy Ellipta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $23.91 | 2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $23.59 | 2025 | Auvelity |
| Astellas Pharma US INC | $21.77 | 2023 | Veozah |
| Janssen Pharmaceuticals, INC | $20.62 | 2024 | Xarelto |
| Exact Sciences Corporation | $20.19 | 2025 | Cologuard Collection Kit |
| Abbott Laboratories | $18.34 | 2024 | Freestyle Libre 3 |
| Antares Pharma, INC. | $14.67 | 2025 | Xyosted |
| Idorsia Pharmaceuticals US INC | $13.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.